Clinical Trial

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-05-19; most recent amendment 2026-05-20.
Trial Details
NCT Number NCT06991114
Lead Sponsor Artiva Biotherapeutics, Inc.
Conditions Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome +1 more
Enrollment 90 participants
Start Date 2025-07-09
Primary Completion 2028-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-31